Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.01 USD
Change Today +0.0012 / 11.88%
Volume 719.1K
GNBT On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

generex biotechnology corp (GNBT) Snapshot

Open
$0.01
Previous Close
$0.01
Day High
$0.01
Day Low
$0.01
52 Week High
10/13/14 - $0.04
52 Week Low
07/20/15 - $0.01
Market Cap
9.1M
Average Volume 10 Days
3.5M
EPS TTM
$-0.0011
Shares Outstanding
805.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENEREX BIOTECHNOLOGY CORP (GNBT)

Related News

No related news articles were found.

generex biotechnology corp (GNBT) Related Businessweek News

No Related Businessweek News Found

generex biotechnology corp (GNBT) Details

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It focuses on its proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. The company’s buccal delivery technology and products include Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using RapidMist hand-held aerosol spray applicator for the treatment of Type 1 and Type 2 diabetes. It is also involved in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases. In addition, the company is developing immunotherapeutic vaccine AE37 that is under Phase II clinical trial for patients with HER-2/neu positive breast cancer; and synthetic peptide vaccines against avian (H5N1) influenza, as well as vaccines against swine (H1N1) influenza. Further, it is developing synthetic peptide vaccines designed to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene that is in Phase II clinical trial for HER-2/neu positive breast cancer; in two Phase I clinical trials for prostate cancer and against avian influenza; and in Phase I clinical trial for breast or ovarian cancer. The company markets its products through collaborative arrangements with various companies worldwide. Generex Biotechnology Corporation was founded in 1983 and is based in Toronto, Canada.

8 Employees
Last Reported Date: 10/3/14
Founded in 1983

generex biotechnology corp (GNBT) Top Compensated Officers

Chief Executive Officer, President, General C...
Total Annual Compensation: $435.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $206.3K
Chief Operating Officer and Secretary
Total Annual Compensation: $206.3K
Compensation as of Fiscal Year 2014.

generex biotechnology corp (GNBT) Key Developments

Generex Biotechnology Corporation Enters into Memorandum of Understanding with NHTherapeutics

Generex Biotechnology Corporation announced that it has entered into a Memorandum of Understanding with NHTherapeutics Inc., pursuant to which the companies will co-develop a formulation for the delivery of Leuprolide into the human body via the buccal mucosa using the Generex proprietary RapidMist(TM) buccal drug delivery system. The Generex proprietary RapidMist(TM) drug delivery platform technology administers active pharmaceutical ingredient via aerosolized metered dose spray into the mouth for rapid absorption by the buccal mucosa. The company's most advanced product in development using RapidMist(TM) is Generex Oral-lyn(TM), an insulin spray product for the treatment of diabetes mellitus. NHTherapeutics holds intellectual property in respect to the dosing regimen and route of administration of Leuprolide and other GnRH agonists for the treatment of hypogonadism and other endocrine disorders. Pursuant to a fee-for-service arrangement, Generex will develop a RapidMist(TM) formulation of Leuprolide designed to achieve the safe, simple, rapid, dose-specific, and effective administration of the active pharmaceutical ingredient into the human body via the buccal mucosa. Thereafter, Generex will undertake local irritation and stability testing of the formulation.

Generex Presents Data Correlating Immune Response with Reduction of Relapse in AE37 Phase II Breast Cancer Trial at AACR 2015

Generex Biotechnology Corp. announced presentation of data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine correlating local immune response to a reduction in relapse. AE37 is being developed by Antigen Express Inc., a wholly-owned subsidiary of Generex. The abstract entitled 'Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a Phase II trial of the AE37+GM-CSF HER2 peptide vaccine' by Julia Greene, et al was presented at the Clinical Trials in Progress session of the AACR on April 20. The goal of the study was to establish the importance of the local reaction to immunization with AE37. The controlled, randomized and single-blinded trial is comparing the ability of AE37 plus the adjuvant GM-CSF versus the GM-CSF adjuvant alone to reduce recurrence of breast cancer in early stage patients. The study found that those patients receiving AE37 who had the large responses (requiring reductions in the amount of GM-CSF) had a relapse rate of 5.9% versus a rate of 14.2% in those who did not require dose reduction. This indicates that a robust stimulation of the immune system by AE37, as evidenced by the need for dose reduction, results in positive anti-cancer activity. The AE37 vaccine is designed to activate critical components of the immune system to combat cancer cells. Prior analyses have shown a trend toward reduction of relapse in patients receiving the vaccine, particularly those who are not eligible for the cancer drug Herceptin as well as those with triple negative breast cancer. The current results add to prior studies both from the ongoing Phase II trial as well as a completed Phase I study of AE37 in patients with prostate cancer showing robust yet specific immunological responses together with almost negligible toxicity. The distinguishing feature of AE37 is its ability to specifically activate CD4+ T helper cells, which govern both the quality and magnitude of an immune response to a novel target.

Generex Biotechnology Corporation Announces Resignation of John P. Barratt as Member of Board of Directors

Generex Biotechnology Corporation announced the resignation of John P. Barratt as a member of the company's Board of Directors. For medical reasons, Mr. Barratt has made the decision to take full retirement from his myriad corporate responsibilities. The resignation from the company’s Board of Directors will take effect on April 30, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNBT:US $0.01 USD +0.0012

GNBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GNBT.
View Industry Companies
 

Industry Analysis

GNBT

Industry Average

Valuation GNBT Industry Range
Price/Earnings 30.0x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 17.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENEREX BIOTECHNOLOGY CORP, please visit www.generex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.